202286-27-9 Usage
Uses
Used in Scientific Research:
1-(5-Bromo-4-methyl-1H-pyrrol-3-yl)ethanone is used as a reagent or intermediate in the synthesis of other compounds for [application reason] in scientific research. Its complex structure and the presence of a bromine atom and a methyl group on the pyrrole ring make it a valuable candidate for various chemical reactions and studies.
Used in Pharmaceutical Industry:
1-(5-Bromo-4-methyl-1H-pyrrol-3-yl)ethanone is used as a building block or intermediate in the development of new pharmaceutical compounds for [application reason] in the pharmaceutical industry. Its unique structure may contribute to the creation of novel drugs with potential therapeutic applications.
Used in Chemical Synthesis:
1-(5-Bromo-4-methyl-1H-pyrrol-3-yl)ethanone is used as a key component in the synthesis of complex organic molecules for [application reason] in the field of chemical synthesis. Its versatility and the presence of functional groups make it a valuable asset in the preparation of a wide range of chemical products.
Check Digit Verification of cas no
The CAS Registry Mumber 202286-27-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,2,8 and 6 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 202286-27:
(8*2)+(7*0)+(6*2)+(5*2)+(4*8)+(3*6)+(2*2)+(1*7)=99
99 % 10 = 9
So 202286-27-9 is a valid CAS Registry Number.
InChI:InChI=1/C7H8BrNO/c1-4-6(5(2)10)3-9-7(4)8/h3,9H,1-2H3
202286-27-9Relevant academic research and scientific papers
PYRIDYLPYRROLE COMPOUNDS USEFUL AS INTERLEUKIN-AND TNF ANTAGONISTS
-
, (2008/06/13)
The present invention provides a compound of the formula: and its pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5 and m are as defined in claim 1. The present invention also provides processes for the preparation thereof, the use thereof in treating cytokines mediated diseases and/or cell adhesion molecules (CAMs) mediated diseases and pharmaceutical compositions for use in such therapy.
